Declan Doogan, Director at Biohaven Pharmaceutical Holding Co Ltd. (BHVN), sold 220,726 shares at $35.04 ($7.7M) on 2018-06-01, disclosed to the SEC on 2018-06-01.
Open-market sale of $7.7M BHVN by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $35.00 | 842 | $29K | 0.4% |
| 2 | $35.01 | 26,044 | $912K | 11.8% |
| 3 | $35.01 | 26,044 | $912K | 11.8% |
| 4 | $35.04 | 83,898 | $2.9M | 38.0% |
| 5 | $35.04 | 83,898 | $2.9M | 38.0% |
| Total | $35.03 avg | 220,726 |
| $7.7M |
| 100% |
| Filing → |
| BHVN | SELL | 2022-02-11 | $5.0M | — | Filing → |
| BHVN | SELL | 2021-12-01 | $5.5M | — | Filing → |
| BHVN | SELL | 2021-11-17 | $8.8M | — | Filing → |